![Chris Hollowood](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Chris Hollowood
Directeur/Membre du Conseil chez
APPLIED GENETIC TECHNOLOGIES CORPORATION
Profil
Dr. Christopher J.
Hollowood is a Chairman at Forcefield Therapeutics Ltd. and a Chief Executive Officer & Chief Investment Officer at Syncona Partners LLP.
He is on the Board of Directors at Beacon Therapeutics (USA), Inc., Spur Therapeutics Ltd. and Syncona Ip Holdco Ltd. Dr. Hollowood was previously employed as a Chairman by Purespring Therapeutics Ltd., a Chairman by SwanBio Therapeutics, Inc., a Chairman by Gyroscope Therapeutics Holdings Plc, a Chairman by Gyroscope Therapeutics Ltd., a Chairman by Freeline Therapeutics Holdings Ltd., a Chairman by Nightstar Therapeutics Plc, a Partner by Apposite Capital LLP, and a Chief Investment Officer by Syncona Ltd. He also served on the board at Convergence Pharmaceuticals Ltd., Bird Rock Bio Sub, Inc., Calchan Holdings Ltd. and NightstaRx Ltd. He received his doctorate degree from the University of Cambridge.
Postes actifs de Chris Hollowood
| Sociétés | Poste | Début |
|---|---|---|
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Directeur/Membre du Conseil | 01/12/2022 |
Forcefield Therapeutics Ltd.
 Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Président | 01/11/2020 |
Syncona Ip Holdco Ltd. | Directeur/Membre du Conseil | - |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Fondateur | 01/01/2015 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Directeur Général | 01/01/2023 |
Anciens postes connus de Chris Hollowood
| Sociétés | Poste | Fin |
|---|---|---|
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Président | 16/10/2023 |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Président | 17/02/2022 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Président | 02/02/2022 |
| NIGHTSTAR THERAPEUTICS PLC | Président | 07/06/2019 |
| ░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Formation de Chris Hollowood
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
81
Relations au 1er degré
18
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 18 |
|---|---|
Syncona Ltd.
 Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical research and development company that provides gene therapy development & clinical research services | Health Technology |
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital invests in companies located in the United Kingdom and European with revenues of up to EUR 100 million. The firm focuses on the technology sector. It provides financing for MBOs, buy-in and growth capital requirements. It also acquires minority interest. | Finance |
Bird Rock Bio Sub, Inc.
 Bird Rock Bio Sub, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops neuropathic pain products | Health Technology |
Calchan Holdings Ltd.
 Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops novel oral state-dependent calcium channel (CaV 2.2) modulators for chronic pain | Health Technology |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Finance |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services development of therapies for retinal dystrophies | Health Services |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Health Technology |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. BiotechnologyHealth Technology Operates as a gene therapy company that develops novel treatments for patients suffering from inherited retinal diseases | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc Pharmaceuticals: MajorHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Health Technology |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Develops clinical-stage gene therapies to treat diseases of eyes | Health Technology |
Forcefield Therapeutics Ltd.
Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Health Technology |
Syncona Ip Holdco Ltd. |
